BSX earnings call for the period ending March 31, 2020.
News & Analysis: Boston Scientific
But a sharp decline in medical procedures caused a drop in first-quarter profits.
The company's Coventor will retail for under $1,000.
The coronavirus outbreak meant the postponement of medical procedures, weighing on Boston Scientific’s revenue.
The company did not offer updated guidance for its full-year fiscal 2020 results.
Revenue prospects after the coronavirus outbreak make these companies a good buy today.
Fewer elective surgery procedures in China may weigh on Boston Scientific’s first-quarter earnings.
Boston Scientific’s recent earnings report was mixed, but FDA clearance of a potentially blockbuster device could drive future revenue -- and stock performance.
BSX earnings call for the period ending December 31, 2019.
The medical device maker posted mixed results in Q4. And the coronavirus outbreak is weighing on its 2020 Q1 outlook.